Investigator
Director, Platform for Cellular Modeling of Neuropsychiatric Disease (cMiND), Center for Genomic Medicine Massachusetts General Hospital
Lecturer, Department of Psychiatry Harvard Medical School
Dr. Sheridan has more than 20 years of experience in both academia and biotech deriving, large-scale bioprocessing, differentiating and characterizing pluripotent and multipotent stem cells and their progeny for the purposes of disease modeling, genetic engineering, cell therapy, tissue engineering, and cell-based HTS drug discovery. His research as Investigator in the Center for Genomic Medicine, Massachusetts General Hospital and Lecturer in the Dept. of Psychiatry, Harvard Medical School involves the generation and characterization of human induced pluripotent stem cells (iPSCs), neural stem cells and microglia from patients of various neuropsychiatric and neurodevelopmental disease backgrounds (Schizophrenia, Bipolar Disorder, Major Depression, Fragile X Syndrome, Rett Syndrome, CDKL5 Deficiency Disorder, Pitt-Hopkins Syndrome, etc.) in order to facilitate the development of novel cell-based assays of disease mechanism. He has also held previous additional appointments in MIT, including developing novel synthetic RNA-based technologies to deliver gene libraries to enable ultra-high throughput screening of candidate target genes. He received his Ph.D. in Molecular Genetics at the University of California, Irvine and followed up with a post-doctoral fellowship in genetic engineering at Harvard University.
Perlis Lab 